Your Expert Resource for COVID-19 Testing

The complete suite of assays & services needed to detect and characterize responses to SARS-CoV-2.

Expert In Clinical Assays

Bioagylitix delivers rebustdata sets abd comprehensive data interpretation beyond what a typical diagnostic lab can offer

Speak to our scientists to get your testing underway today. Call us directly at +1 919-381-6097 or complete this request form.

As experts in clinical assays, BioAgilytix delivers robust data sets and comprehensive data interpretation beyond what a typical diagnostic lab can offer.

We also offer the breadth of testing needed to determine disease state, characterize antibody response, and assess biomarkers related to SARS-CoV-2, the virus associated with COVID-19.

Our assays are helping the global pharma & biotech community address the immediate threats of COVID-19 with new vaccine and anti-viral therapeutic programs, and also look ahead at how patients with antibodies to SARS-CoV-2 might impact and change clinical trial strategies moving forward.

Robust Data Sets

We specialize in assays for clinical trials, so our results will stand up to stringent regulatory submission requirements.

CLIA-Certified Labs

Our Boston, MA and Durham, NC labs can perform testing under CLIA to support patient enrollment in clinical trials

A Personalized Approach

We’re able to tailor our testing strategies to your unique program, and can support development of de novo assays.


BioAgilytix uses the RT-PCR assay with Emergency Use Authorization (EUA) by the FDA to specifically detect the RNA of SARS-CoV-2 to identify active or recent infections.

pcr testing for covid-19

Our PCR testing can be applied under CLIA for:

Diagnostic/ Screening Tests

Assisting Companies in Starting & Restarting Clinical Trials

Our PCR testing offers high specificity and precise quantification, and we can provide results with speed.


BioAgilytix’s highly specific immune response assays detect IgA, IgM, and IgG antibodies to identify individuals who were infected and have already recovered from COVID-19.

Vaccine Clinical Trials Support
Patient Stratification for Clinical Trials

Why BioAgilytix for your antibody testing needs?

In addition to qualitative assessments, we are also able to provide semi-quantitative measurements (titer) to assess a patient’s relative levels (magnitude of the response) which indicate stage of infection and strength of antibody response.

Complete package of covid-19 testing
To disscuss your program requirements, contact your BioAgilytix representative or reach out to us and we’ll connect you to the appropriate scientists to get started
US: +1 919-381-6097 | Europe: +49 40 526779 0


Emerging data suggests that CRS in patients with severe cases of COVID-19 may cause death. BioAgilytix can apply our validated MSD cytokine/chemokine panels to quantify these biomarkers in patients receiving novel therapeutics for the treatment of COVID-19.

These panels have undergone full bioanalytical validation at BioAgilytix and are already utilized to support a broad range of clinical trials today.

Biacore Isotype Switching


Using our Biacore™ T200 platform, we are also able to assess immune response as well as characterize isotype switching to distinguish fresh infection from later infection and determine antibody affinities to define antibody maturation.

Biacore is available at our European lab in Hamburg, Germany and with it we are able to conduct highly specific analysis with efficient time-to-result.


We’re committed to applying our specialized expertise and proven processes to help our customers test for and understand the impacts of the novel COVID-19 disease. And with fully operational labs, we’re ready to help today..

The detection of antibodies against SARS-CoV-2 supports


Tell us a little more about your needs for testing related to SARS-CoV-2 and the associated COVID-19 disease. We’ll get back to you right away to discuss how we can help.

Speak To A Scientist

    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.